Medicis Pharmaceutical Corporation (MRX)

36.73 -0.35  -0.94%  May 30, 5:20PM Go Pro
Watch this stock
View Full Chart MRX Price Chart

Key Stats

Market Cap 2.164B
Revenue Growth 22.33%
Profit Margin 2.65%
Earnings Yield 4.55%
Dividend Yield 1.11%
Earnings Per Share TTM 1.67
PE Ratio 21.99
Price / Sales Ratio 2.855
52 Week High 40.51
52 Week Low 29.76
Beta 1.246
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 25 Medicis Sued by Revance Therapeutics Over Wrinkle-Gel Pact
May 25 $MRX Mentioned more than normal on StockTwits - Currently at 8 x average daily social activity by TradeIdeasQuant
May 25 HIGH $CALL VOLU $ALB 1852% $SFL 1299% $BZH 982% $MRX 970% $PBY 798% $NOC 791% $SNV 756% $OLN 753% $AVGO 595% $EWA 575% by livevol_pro
May 25 IV30(TM) GAINER $ELN +20.09% $MRX +10.41% $IOC +5.84% $CALL +5.7% by livevol_pro
May 25 HIGH $CALL VOLU $SFL 1035% $BZH 982% $MRX 970% $NOC 790% $SNV 747% $OLN 744% $EWA 572% $AVGO 572% $TTM 403% $ASH 370% by livevol_pro
May 25 Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX Street Insider
May 25 Goldman Calls Medicis (MRX) 'One of the Most Likely M&A Targets' in Specialty Pharma ...
May 25 Obagi Puts Its Problems Behind It
May 25 IV30(TM) GAINER $MRX +14.21% $ELN +11.33% by livevol_pro
May 25 HIGH $CALL VOLU $MRX 963% $NOC 766% $SNV 745% $KSS 215% $HYG 185% $VOD 121% $HL 111% $MRO 104% $CHK 88% $FLR 85% by livevol_pro
May 25 Goldman Pharma View: Buy AGN, Sell FRX, MRX A Takeover Target

Profile

Exchange: NYSE       Sector: Healthcare       Industry: Drugs - Generic

Medicis Pharmaceutical Corporation is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Medicis is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis Pharmaceutical operates in one business segment: Pharmaceuticals. The Pharmaceutical segment comprises of Dermatological and Non-Dermatological businesses. The Dermatological business represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder, noninvasive body sculpting technology and contract revenue. The company was founded on July 28, 1988 by Jonah Shacknai and is headquartered in Scottsdale, Arizona.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Medicis Pharmaceutical Corporation is down 1.27% over the last year vs S&P 500 Total Return up 2.32%, Salix Pharmaceuticals up 33.03%, and Watson Pharmaceuticals up 13.25%.

  • MRX Total Returns
  • ^SPXTR Total Returns
  • SLXP Total Returns
  • WPI Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring MRX

Did Medicis Pharmaceutical Corporation make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

MRX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
MRX 36.73 -0.35 -0.94% 2.185B
MRVL 12.74 -0.31 -2.38% 7.647B
MRO 24.86 -0.66 -2.59% 17.97B
MRNAD 0.7203 -0.09 -11.07%
MRNA 0.7389 +0.02 +2.58% 5.842M
MRLN 13.98 -0.39 -2.71% 182.64M
MRK 37.41 -0.18 -0.48% 114.42B
MRH 20.44 -0.10 -0.49% 1.219B
MRGE 2.40 -0.08 -3.23% 225.70M
MRF 7.84 -0.06 -0.76%
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close